Medy-Tox Inc. (KOSDAQ:086900)

Market Cap	838.82B
Revenue (ttm)	234.63B
Net Income (ttm)	18.22B
Shares Out	7.02M
EPS (ttm)	2,832.89
PE Ratio	42.18
Forward PE	21.92
Dividend	1,100.00 (0.92%)
Ex-Dividend Date	Sep 27, 2024

Volume	28,898
Average Volume	58,598
Open	119,300
Previous Close	120,200
Day's Range	119,100 - 120,500
52-Week Range	112,100 - 210,500
Beta	0.39
RSI	26.80
Earnings Date	Aug 12, 2025

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 724
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086900

Financial Performance

In 2024, Medy-Tox's revenue was 228.62 billion, an increase of 3.39% compared to the previous year's 221.12 billion. Earnings were 15.98 billion, an increase of 82.00%.